DS
INKT icon

DRW Securities’s MiNK Therapeutics INKT Stock Holding History

DRW Securities’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,677
Closed -$286K – 1512
2025
Q4 		$286K Buy
+25,677
New +$332K 0.01% 702

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

DRW Securities's INKT Position: Q1 2026 in Review

DRW Securities sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 25,677 shares — an estimated $286K sold.

DRW Securities first reported a position in INKT in Q4 2025 and held it in 1 quarter. The position peaked at $286K in Q4 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • DRW Securities reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 25,677 MiNK Therapeutics shares in Q1 2026, an estimated $286K.
  • DRW Securities first reported a position in MiNK Therapeutics in Q4 2025 and held it in 1 quarter.
  • DRW Securities's MiNK Therapeutics position peaked at $286K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.